Analysts Have Conflicting Sentiments on These Healthcare Companies: Ultragenyx (RARE) and Teva Pharma (TEVA)


Analysts have been eager to weigh in on the Healthcare sector with new ratings on Ultragenyx (NASDAQ:RARE) and Teva Pharma (NYSE:TEVA).

Ultragenyx (RARE)

In a report released today, Gena Wang from Barclays maintained a Buy rating on Ultragenyx, with a price target of $92. The company’s shares closed on Friday at $71.81.

According to TipRanks.com, Wang is a 5-star analyst with an average return of 24.9% and a 53.0% success rate. Wang covers the Healthcare sector, focusing on stocks such as Ionis Pharmaceuticals Inc, Sarepta Therapeutics, and Mirati Therapeutics.

Currently, the analyst consensus on Ultragenyx is a Strong Buy with an average price target of $85.91, implying a 19.6% upside from current levels. In a report issued on August 2, J.P. Morgan also maintained a Buy rating on the stock with a $86 price target.

.

See today’s analyst top recommended stocks >>

Teva Pharma (TEVA)

Barclays analyst Douglas Tsao maintained a Hold rating on Teva Pharma today and set a price target of $23. The company’s shares closed on Friday at $22.17.

According to TipRanks.com, Tsao is a 2-star analyst with an average return of 1.1% and a 51.4% success rate. Tsao covers the Healthcare sector, focusing on stocks such as Bausch Health Companies Inc, Protagonist Therapeutics, and Pacira Pharmaceuticals.

Teva Pharma has an analyst consensus of Hold, with a price target consensus of $22.91, a 3.3% upside from current levels. In a report issued on July 31, RBC Capital also reiterated a Hold rating on the stock with a $19 price target.

.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on TEVA:

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts